Data announced ahead of this year’s American Society of Clinical Oncology (ASCO) conference suggest that Gilead and CAR-T rivals Bristol-Myers Squibb and Novartis better watch their backs as Allogene announced plans for a pivotal study this year.
Allogeneic or “off the shelf” cancer cell therapies are derived from a bank of cells and can be manufactured and administered in bulk like drugs.
Meanwhile the autologous CAR-Ts already approved and on the market require patients’ T-cells to be harvested and genetically modified to fight cancer, an expensive and time-consuming process.